NASDAQ: ITOSIteos Therapeutics Inc Stock
$11.42-0.65 (-5.39%)
Updated Sep 22, 2023
ITOS Price
$11.42
Fair Value Price
N/A
Market Cap
$408.63M
52 Week Low
$11.33
52 Week High
$23.00
P/E
-14.46x
P/B
0.66x
P/S
5.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$85.99M
Earnings
-$28.41M
Gross Margin
100%
Operating Margin
-31%
Profit Margin
-33%
Debt to Equity
0.13
Operating Cash Flow
-$113M
Beta
1.11
Next Earnings
Nov 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ITOS Overview
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ITOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ITOS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ITOS is good value based on its book value relative to its share price (0.66x), compared to the US Biotechnology industry average (5.11x)
P/B vs Industry Valuation
ITOS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ITOS due diligence checks available for Premium users.
Be the first to know about important ITOS news, forecast changes, insider trades & much more!
ITOS News
Valuation
ITOS fair value
Fair Value of ITOS stock based on Discounted Cash Flow (DCF)
Price
$11.42
Fair Value
$18.58
Undervalued by
38.54%
ITOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ITOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.46x
Industry
12.89x
Market
14.52x
ITOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.66x
Industry
5.11x
ITOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ITOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$34.3M
Profit Margin
0%
ITOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ITOS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$703.7M
Liabilities
$80.2M
Debt to equity
0.13
ITOS's short-term assets ($614.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITOS's short-term assets ($614.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.5M
Investing
$20.1M
Financing
$218.0k
ITOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ITOS vs Biotech Stocks
Iteos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.